Detailed Information
Cited 9 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm(+)) non-small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis
- Authors
- Wu, YL[Wu, Yi-Long]; Zhou, Q[Zhou, Qing]; Wang, J[Wang, Jie]; Yu, Y[Yu, Yan]; Xing, LG[Xing, Ligang]; Wang, Y[Wang, Ying]; Cheng, Y[Cheng, Ying]; Pan, YY[Pan, Yueyin]; Fan, Y[Fan, Yun]; Shi, JH[Shi, Jianhua]; Zhang, GJ[Zhang, Guojun]; Cui, JW[Cui, Jiuwei]; Zhou, JY[Zhou, Jianying]; Song, Y[Song, Yong]; Zhuang, W[Zhuang, Wu]; Ma, ZY[Ma, Zhiyong]; Hu, YP[Hu, Yanping]; Li, GF[Li, Gaofeng]; Dong, XR[Dong, Xiaorong]; Ahn, MJ[Ahn, Myung-Ju]
- Issue Date
- 1-Jun-2023
- Publisher
- LIPPINCOTT WILLIAMS & WILKINS
- Citation
- JOURNAL OF CLINICAL ONCOLOGY, v.41, no.16
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF CLINICAL ONCOLOGY
- Volume
- 41
- Number
- 16
- ISSN
- 0732-183X
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.